Want to see FULC full AI Analyst Report?
FULC Stock Chart & Stats
$3.86
-$0.04(-1.06%)
At close: 4:00 PM EDT
$3.86
-$0.04(-1.06%)
Day’s Range― - ―
52-Week Range$2.83 - $15.74
Previous CloseN/A
Volume572.86K
Average Volume (3M)2.55M
Market Cap
$293.74M
Enterprise Value-$34.44
Total Cash (Recent Filing)$318.84M
Total Debt (Recent Filing)$5.28M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.21
Shares Outstanding76,297,260
10 Day Avg. Volume1,424,404
30 Day Avg. Volume2,547,280
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)2.05
Price to Sales (P/S)0.00
P/FCF Ratio-11.87
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$3.33Price Target Upside-13.64% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering8
EPS Forecast (FY)-0.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Transaction And Cash ReturnThe proposed merger provides a defined liquidity event for existing holders, with an estimated $270M dividend before closing. If completed, this could return substantial cash while resolving uncertainty around Fulcrum’s standalone future.
Funded Successor PipelineThe committed financing gives the post-merger company resources to advance SLTE-1009 and other pipeline programs through multiple development stages. This improves funding visibility and reduces immediate dependence on capital markets.
Low Financial LeverageFulcrum’s minimal debt limits near-term solvency and interest-burden risk. Although the company remains loss-making, its largely equity-funded balance sheet provides greater flexibility during the transaction process and strategic transition.
Bears Say
Core Drug Program DiscontinuedEnding pociredir removes the company’s principal clinical development asset despite encouraging efficacy data. The FDA’s safety assessment eliminates the prior regulatory path and materially weakens Fulcrum’s standalone biotechnology investment case.
No Commercial Revenue And Persistent LossesFulcrum has no marketed products or stable operating revenue, so funding depends on cash reserves, transactions, or future financing. Continued losses and substantial cash burn can erode its capital base if strategic execution is delayed.
Major Restructuring And Transaction DependenceThe workforce reduction sharply limits standalone discovery and development capacity, while the proposed merger shifts control and strategic focus to Slate. Until closing, execution, approval, and transition risks remain material for shareholders.
Fulcrum Therapeutics News
FULC FAQ
What was Fulcrum Therapeutics’s price range in the past 12 months?
Fulcrum Therapeutics lowest stock price was $2.83 and its highest was $15.74 in the past 12 months.
What is Fulcrum Therapeutics’s market cap?
Fulcrum Therapeutics’s market cap is $293.74M.
When is Fulcrum Therapeutics’s upcoming earnings report date?
Fulcrum Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 58 days.
How were Fulcrum Therapeutics’s earnings last quarter?
Fulcrum Therapeutics released its earnings results on Aug 05, 2026. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.291 by $0.021.
Is Fulcrum Therapeutics overvalued?
According to Wall Street analysts Fulcrum Therapeutics’s price is currently Overvalued.
Does Fulcrum Therapeutics pay dividends?
Fulcrum Therapeutics does not currently pay dividends.
What is Fulcrum Therapeutics’s EPS estimate?
Fulcrum Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fulcrum Therapeutics have?
Fulcrum Therapeutics has 76,297,260 shares outstanding.
What happened to Fulcrum Therapeutics’s price movement after its last earnings report?
Fulcrum Therapeutics reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.291. Following the earnings report the stock price went down -0.789%.
Which hedge fund is a major shareholder of Fulcrum Therapeutics?
Currently, no hedge funds are holding shares in FULC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fulcrum Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$3.33 (-13.64% Downside)
$3.33 (-13.64% Downside)
Blogger Sentiment
Bullish
FULC Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 5.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $594.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 12.6%
Last 30 Days ▼ 12.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
42.91%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Fulcrum Therapeutics
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
FULC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive clinical momentum for potociredir — notably a large, rapid increase in HbF, early VOC reduction signals and a clean safety profile — paired with a solid balance sheet and a clear plan for regulatory interactions and a potential registration-enabling trial. Offsetting risks include modestly higher operating losses and expenses, a quarterly cash decline (while runway remains into 2029), delayed availability of meaningful long-term OLE data (likely into 2027), ongoing regulatory uncertainty about surrogate endpoints and emerging competition in the oral HbF inducer space. Overall, the clinical and financial highlights outweigh the operational and regulatory uncertainties.View all FULC earnings summariesFULC Stock 12 Month Forecast
Average Price Target
$3.33
▼(-13.64% Downside)
Technical Analysis
Monopar Therapeutics Inc
―
ADC Therapeutics
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
18.23% Insiders
7.44% Mutual Funds
41.36% Other Institutional Investors
21.05% Public Companies and
Individual Investors